Overview

Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Status:
Completed

Trial end date:
2004-06-17

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with ITP.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen